Related Experiment Video
Updated: Aug 7, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
Potassium-sparing agents during diuretic therapy in hypertension
British Medical Journal
|June 26, 1971
Summary
Spironolactone and Slow-K effectively preserved potassium levels during diuretic therapy in hypertensive patients. Plasma potassium was an unreliable indicator of total body potassium restoration.
Area of Science:
- Pharmacology
- Nephrology
- Cardiovascular Medicine
Background:
- Diuretic therapy for hypertension can lead to potassium depletion.
- Potassium-sparing agents are used to mitigate this side effect.
- Accurate assessment of potassium balance is crucial.
Purpose of the Study:
- To evaluate the efficacy of three potassium-sparing agents in hypertensive patients undergoing diuretic therapy.
- To assess the impact of these agents on total exchangeable potassium (K(E)).
- To determine the reliability of plasma potassium levels in reflecting K(E) restoration.
Main Methods:
- Serial measurements of total exchangeable potassium (K(E)) were performed.
- Hypertensive subjects received oral diuretic therapy for 4 to 12 weeks.
- Three agents were tested: Triamterene, Spironolactone, and Slow-K.
Main Results:
- Triamterene (50 mg twice daily) showed limited efficacy.
- Spironolactone (25 mg twice daily) significantly reduced potassium loss.
- Slow-K (32 mEq daily) completely reversed pre-existing potassium deficits.
- Plasma potassium levels did not accurately indicate the extent of K(E) restoration.
Conclusions:
- Spironolactone and Slow-K are effective in preserving potassium balance during diuretic treatment.
- Triamterene may be less effective at the tested dosage.
- Plasma potassium monitoring alone is insufficient for assessing total body potassium status.
Related Concept Videos
01:16Antihypertensive Drugs: Action of Diuretics
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...